Imunon, Inc. Reports Board and Executive Changes
Ticker: IMNN · Form: 8-K · Filed: Mar 12, 2024 · CIK: 749647
Sentiment: neutral
Topics: management-change, compensation
TL;DR
Board shakeup at Imunon, Inc. - new directors in, exec comp updated.
AI Summary
Imunon, Inc. announced on March 6, 2024, a change in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory plans.
Why It Matters
Changes in a company's board and executive compensation can signal shifts in strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can introduce uncertainty about the company's future direction and stability.
Key Players & Entities
- Imunon, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- March 6, 2024 (date) — Date of earliest event reported
FAQ
What specific roles have been affected by the departure of officers and directors?
The filing indicates changes related to 'Departure of Directors or Certain Officers' and 'Appointment of Certain Officers', but does not specify the exact roles vacated or filled in this summary.
What are the key changes in compensatory arrangements for the officers?
The filing mentions 'Compensatory Arrangements of Certain Officers' as an item of report, indicating updates or new arrangements, but the specifics are not detailed in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on March 6, 2024.
What is Imunon, Inc.'s Standard Industrial Classification (SIC) code?
Imunon, Inc.'s SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Has Imunon, Inc. undergone any previous name changes?
Yes, Imunon, Inc. was formerly known as Celsion Corp (name change on November 21, 2007) and prior to that, CELSION CORP (name change on May 15, 1998), and CHEUNG LABORATORIES INC (name change on July 3, 1992).
Filing Stats: 660 words · 3 min read · ~2 pages · Grade level 10.3 · Accepted 2024-03-12 17:05:19
Key Financial Figures
- $0.01 — ch registered Common stock, par value $0.01 per share IMNN Nasdaq Capital Mark
Filing Documents
- form8-k.htm (8-K) — 39KB
- ex99-1.htm (EX-99.1) — 16KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- 0001493152-24-009684.txt ( ) — 234KB
- imnn-20240306.xsd (EX-101.SCH) — 3KB
- imnn-20240306_lab.xml (EX-101.LAB) — 33KB
- imnn-20240306_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMUNON INC. Dated: March 12, 2024 By: /s/ Jeffrey W. Church Jeffrey W. Church Executive Vice President and Chief Financial Officer